This inventor holds 1 USPTO granted patent. Top assignee: Johns Hopkins University. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Huili Li: Innovator in Epigenetic Drug Therapy
Introduction
Huili Li is a prominent inventor based in Ellicott City, MD (US). He has made significant contributions to the field of epigenetics, particularly in predicting responses to epigenetic drug therapies. His innovative work has the potential to transform treatment strategies for patients undergoing such therapies.
Latest Patents
Huili Li holds a patent titled "Predicting response to epigenetic drug therapy." This invention provides methods and compositions that are useful for predicting how patients will respond to epigenetic drug therapies. The invention identifies a unique signature known as the AZA Immune gene set (AIM), which differentiates patients based on their immune signatures. Patients with a high immune signature may benefit from immunotherapies, while those with a low immune signature may require treatment with epigenetic drugs followed by immunotherapy.
Career Highlights
Huili Li is affiliated with The Johns Hopkins University, where he conducts research and develops innovative solutions in the field of epigenetics. His work has garnered attention for its potential to improve patient outcomes in cancer treatment and other diseases influenced by epigenetic factors.
Collaborations
Huili Li collaborates with esteemed colleagues, including Nita Ahuja and Stephen B Baylin. These partnerships enhance the research efforts and contribute to the advancement of knowledge in epigenetics.
Conclusion
Huili Li's contributions to the field of epigenetics through his innovative patent and collaborative efforts at The Johns Hopkins University highlight his role as a key inventor in advancing medical therapies. His work promises to improve the precision of treatments for patients, paving the way for more effective healthcare solutions.